The global AI for Cancer Diagnosis market size is predicted to grow from US$ 286 million in 2025 to US$ 1719 million in 2031; it is expected to grow at a CAGR of 34.9% from 2025 to 2031.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.

Segmentation by Type:

• Breast Cancer
• Lung Cancer
• Prostatic Cancer
• Others

Segmentation by Application:

• Hospital
• Clinic
• Other

This report also splits the market by region:

Americas

• United States
• Canada
• Mexico
• Brazil

APAC

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

Europe

• Germany
• France
• UK
• Italy
• Russia

Middle East & Africa

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration:

• Lunit Inc
• Xilis
• Shukun Technology
• Kheiron
• SkinVision
• Infervision
• Imagene AI
• Oncora Medical
• Niramai Health Analytix
• Enlitic
• Maxwell Plus
• Therapixel
• Ibex
• OrigiMed
• Tencent

Key Questions Addressed in this Report